Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.75 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.75 |
| ▸ | BRD4 | O60885 | 18/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154729 | 0.86 | STK17B (1.00) | STK17BSTK17ABRD4TDP1 | |
| SCHEMBL3868126 | 0.84 | STK17B (0.79) | STK17BSTK17ABRD4TDP1 | |
| SCHEMBL23409124 | 0.84 | STK17B (0.79) | STK17BSTK17ABRD4TDP1 | |
| SCHEMBL13518095 | 0.83 | STK17B (0.77) | STK17BSTK17ABRD4TDP1 | |
| SCHEMBL29802555 | 0.80 | STK17A (0.72) | STK17BSTK17ABRD4 | |
| SCHEMBL3387315 | 0.80 | STK17A (0.72) | STK17BSTK17ABRD4 | |
| SCHEMBL16088346 | 0.79 | STK17B (0.52) | STK17BSTK17ABRD4 | |
| SCHEMBL11909214 | 0.79 | STK17B (0.67) | STK17BSTK17ABRD4 | |
| SCHEMBL4549833 | 0.79 | STK17B (0.67) | STK17BSTK17ABRD4TDP1 | |
| SCHEMBL2723366 | 0.79 | STK17B (0.67) | STK17BSTK17ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167114-A1 | MACROCYCLIC JAK INHIBITOR AND USE THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4159735-A1 | MACROCYCLIC JAK INHIBITOR AND USE THEREOF | Biopolar Hongye (Guangdong) Pharmaceutical Co. Ltd (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021238817-A1 | MACROCYCLIC JAK INHIBITOR AND USE THEREOF | 百极弘烨（广东）医药科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167114-A1 | MACROCYCLIC JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, JAK3 | STK17B 194/4885STK17A 84/4885BRD4 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.